Jump to any asset
849 assets, updated daily
As of October 10, 2026, Bristol-Myers Squibb Company (BMY) trades at $59.12. CleaRank Financial AI rates it Hold with a fair value of $68.00, 15.0% above the current price. Wall Street's consensus target is $68.00 across 28 analysts. RSI at 34 is in neutral territory, and the price is below its 50-day average of $64.12.
Bristol-Myers Squibb Company (BMY)
Bristol-Myers Squibb Company NYSE
$59.12
-0.4600 (-0.77%)
At close: Oct 9, 4:00 PM EDT
AI Analyst Consensus
59 / 100
Bristol-Myers Squibb Company (BMY) is currently trading at $59.12, below its 50-day and 200-day moving averages ($64.12 and $59.53), indicating a bearish technical trend. The company has demonstrated positive earnings surprises in recent quarters, notably a 27.5% beat in the quarter to June 2026, which saw a 0.69% price increase. However, insider activity shows a moderate sell signal, with over $5 million in sales against $202.2 thousand in purchases in recent filings. Analyst sentiment is mixed, with a consensus 'Hold' rating and a median price target of $68.00, implying a 15% upside. While revenue growth is projected to be positive for the current year at 3.00%, it is expected to decline by 3.00% next year. The company's profit margin stands at 18.87% and return on equity at 46.60%, which are strong figures, but the stock's current valuation metrics and insider selling warrant caution.
BMY Price Analysis
Market Metrics
Open
$58.88
Day Range
$58.74 to $59.79
Prev Close
$59.58
Volume
9.25M
52-Week Range
$42.52 to $68.64
Market Cap
$120.77B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Trading at a notable discount to sector peers (-59%), which may indicate undervaluation or specific company headwinds.
BMY Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 4 quarters, BMY beat estimates 4 times. The stock rose 3 times the next day. Price tends to react positively to beats.
BMY Analysis
Company's Health
3/5
12-Month Analyst Target
+15.02% Upside
Median of 28 analysts (12-month)
$68.00
AI Technical Analysis
Bristol-Myers Squibb (BMY) exhibits bearish momentum with its Relative Strength Index (RSI) at 33.71, signaling oversold conditions that could precede a bounce but indicating a lack of buying pressure. The stock is trading below its 50-day ($64.12), 200-day ($59.53), and 20-day ($61.62) moving averages, reinforcing the current downtrend. Key support levels are being tested as the price hovers near its 200-day SMA. Volume has been below average recently, suggesting a lack of conviction from traders. The MACD indicator is also negative, further supporting the bearish short-term outlook. Investors should watch for a potential reversal if the RSI moves above 50 and the stock can reclaim its key moving averages.
ProTips
- Bristol-Myers Squibb (BMY) offers a dividend yield of approximately 4.26%, providing income to investors, but this should be weighed against the projected revenue decline and moderate insider selling.
- The stock's RSI is in oversold territory, suggesting a potential for a short-term bounce, but confirmation requires breaking above key resistance levels around its 50-day and 200-day moving averages.
- Given the moderate insider selling and projected revenue slowdown, investors may consider a more conservative position sizing or waiting for clearer signs of a fundamental turnaround before increasing exposure.
Key Catalysts
Bullish
Strong Earnings Beat in Q2 2026
Bristol-Myers Squibb (BMY) exceeded EPS estimates by 27.5% in its latest reported quarter (to June 2026), leading to a positive stock price reaction, indicating operational strength.
Source: Company Earnings ReportBearish
Moderate Insider Selling Signal
Insiders have sold over $5 million in BMY stock against $202.2 thousand in purchases, triggering a 'Moderate Sell Signal' and suggesting a lack of internal confidence in near-term price appreciation.
Source: Insider Transaction FilingsBearish
Negative Revenue Growth Projection for 2027
Wall Street revenue estimates indicate a projected sales decline of 3.00% for next year, posing a risk to future earnings and potentially impacting investor sentiment.
Source: Analyst EstimatesNeutral
Mixed Analyst Ratings
While the median price target suggests upside, the majority of analysts rate BMY as 'Hold', reflecting uncertainty about future growth drivers and the stock's current trajectory.
Source: Analyst Consensus DataMarket Outlook
Bristol-Myers Squibb (BMY) is expected to maintain a 'Hold' rating with a median analyst price target of $68.00, suggesting a modest 15% upside from its current trading price of $59.12. The company's strong profit margins and attractive valuation relative to sector peers provide a supportive fundamental backdrop. However, projected revenue contraction in the next fiscal year and a bearish technical setup present near-term challenges. Potential catalysts for upside include continued earnings beats and successful product pipeline advancements, which could shift analyst sentiment and drive the stock towards its higher price targets. Conversely, a failure to reverse the negative revenue trend, increased insider selling, or broader market weakness could push the stock towards its lower support levels, potentially testing the $40 price target range.
Key Statistics
| Market Cap | 120.77B |
|---|---|
| P/E Ratio | 13.09 |
| EPS (TTM) | 4.54 |
| Dividend Yield | 4.26% |
| 52 Week High | 68.64 |
| 52 Week Low | 42.52 |
Bristol-Myers Squibb (BMY) trades at a Price-to-Earnings (P/E) ratio of 13.09, which is significantly below the sector median of 31.9, suggesting a potentially attractive valuation. Its Price-to-Sales (P/S) ratio of 2.47 is also below the sector average of 3.7. The company boasts a strong profit margin of 18.87% and an impressive return on equity of 46.60%, indicating efficient operations and profitability. Despite these favorable fundamental metrics, forward revenue growth estimates suggest a slowdown, with next year's revenue projected to decrease by 3.00%. The company's debt-to-equity ratio stands at 2.02, which is higher than the sector average of 2.02, but within a manageable range given its profitability. The current valuation appears compelling relative to sector averages, but the projected revenue decline and insider selling raise concerns about future growth prospects.
Earnings & Growth Analysis
Bristol-Myers Squibb (BMY) recently reported a strong earnings beat for the quarter ending June 2026, with actual EPS of $2.04 surpassing estimates by 27.5% and leading to a 0.69% stock price increase. This follows a pattern of positive earnings surprises, including a significant 74.34% beat in the quarter to March 2026, though that quarter also saw a substantial reported loss. The company's current year EPS estimate is $6.95, with projected growth of 13% for the year, but a decline of 5.5% is anticipated next year.
Key Risks
Bristol-Myers Squibb (BMY) faces risks from moderate insider selling, with over $5 million in sales by insiders in the recent period, signaling potential concerns about future performance. The stock is also trading below key technical indicators, including its 50-day and 200-day moving averages, indicating a bearish trend. Also, forward revenue growth projections are negative for next year, suggesting potential headwinds for top-line expansion.
Technical Indicators
| RSI (14) | 33.71 |
|---|---|
| MACD | -1.32 |
| SMA 50 | 64.12 |
| SMA 200 | 59.53 |
RSI
Bearish
SMA Cross
Bullish
Price vs SMA
Bearish
MACD
Bearish
Golden Cross in effect with the 50-day SMA ($64.12) above the 200-day SMA ($59.53), price is trading below the 50-day SMA.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.17
Weak correlation
Nasdaq 100 (QQQ)
+0.04
Weak correlation
Bitcoin (BTC)
-0.03
Weak correlation
Gold (XAU)
+0.05
Weak correlation
Check Custom Correlation
How does any other asset move with BMY? One year of daily closes, Pearson correlation.
Try
BMY Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Entry Strategies pick an entry style
Conservative
$58.53
Slight discount to current
Wait for small dip
Aggressive
$59.12
At current price
Enter now if confident
Risk Management
STOP LOSS
$56.77
MAX LOSS
-3.0%
Volatility-Adjusted Stop Loss
Calculated based on RSI (33.7) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$60.28
+3% (Conservative)
+2.0% (Aggressive)
TARGET 2
$61.46
+5% (Conservative)
+4.0% (Aggressive)
TARGET 3
$63.21
+8% (Conservative)
+6.9% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for BMY is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on October 10, 2026.Growth of $10,000
A $10,000 investment in BMY in October 2016 would be worth about $11,869 today, compared with about $36,018 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in BMY today could grow to about $15,056 by 2036 in the base case, with a bull case near $41,415 and a bear case around $5,474. Projections are statistical simulations, not guarantees.
BMY Stock Price Prediction: 2030
CleaRank's simulation projects a price near $69.63 for BMY by 2030 in the base case, from $59.12 today (1.2x over 4 years). The downside path ends near $36.72. These are outcomes of a Monte Carlo simulation run on BMY's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $44.72 | $61.59 | $84.81 |
| 2028 | $40.81 | $64.16 | $101 |
| 2029 | $38.40 | $66.84 | $116 |
| 2030 | $36.72 | $69.63 | $132 |
| 2031 | $35.47 | $72.54 | $148 |
| 2032 | $34.51 | $75.57 | $165 |
| 2033 | $33.77 | $78.73 | $184 |
| 2034 | $33.18 | $82.02 | $203 |
| 2035 | $32.72 | $85.44 | $223 |
| 2036 | $32.36 | $89.01 | $245 |
Method: 10,000 simulated price paths using BMY's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
BMY Insider Trading Analysis
Bought
$202.2K
1 Transactions
Sold
$5.0M
6 Transactions
Insiders
15
Active Traders
Avg Transaction
$737.2K
Moderate size
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Feb 6, 2023 | CAFORIO GIOVANNI
Chief Executive Officer
|
Sell | 240.0K | $17.9M |
| Jul 30, 2021 | VESSEY RUPERT J
Officer
|
Sell | 158.4K | $10.8M |
| Dec 4, 2017 | LEUNG SANDRA
General Counsel
|
Sell | 156.6K | $9.9M |
| Sep 13, 2022 | ELKINS DAVID VINCENT
Chief Financial Officer
|
Sell | 134.0K | $9.6M |
| Aug 13, 2020 | LEUNG SANDRA
General Counsel
|
Sell | 141.4K | $8.9M |
| Aug 12, 2021 | ELKINS DAVID V
Chief Financial Officer
|
Sell | 99.7K | $6.7M |
| Mar 16, 2022 | VESSEY RUPERT J
Officer
|
Sell | 74.6K | $5.2M |
| Mar 2, 2020 | VESSEY RUPERT J
Officer
|
Sell | 84.3K | $5.1M |
| Jun 6, 2022 | LEUNG SANDRA
General Counsel
|
Sell | 65.0K | $4.9M |
| Nov 7, 2022 | VESSEY RUPERT J
Officer
|
Sell | 45.9K | $3.6M |
Page 1 of 1
Frequently Asked Questions
What is Bristol-Myers Squibb's stock price forecast for 2030?
Based on Monte Carlo simulations, Bristol-Myers Squibb's (BMY) stock price is projected to be $69.63 in 2030 under a base case scenario. The downside projection is $36.72, while the upside scenario reaches $132.05. These figures represent statistical outcomes and are not guarantees.
Is Bristol-Myers Squibb stock a buy right now?
Bristol-Myers Squibb (BMY) currently holds a 'Hold' consensus rating from Wall Street analysts, with a median price target of $68.00, implying a 15% upside from its current price of $59.12. While the stock appears undervalued relative to sector peers, moderate insider selling and a bearish technical trend suggest caution.
What are the key risks for Bristol-Myers Squibb?
Key risks for Bristol-Myers Squibb (BMY) include moderate insider selling totaling over $5 million, a bearish technical trend indicated by its price trading below key moving averages, and projected negative revenue growth for the next year.
How did Bristol-Myers Squibb perform in its latest earnings report?
In the quarter to June 2026, Bristol-Myers Squibb (BMY) exceeded earnings expectations by 27.5%, reporting $2.04 in EPS against an estimate of $1.60, which corresponded with a 0.69% stock price increase.
What is Bristol-Myers Squibb's valuation compared to its sector?
Bristol-Myers Squibb (BMY) trades at a P/E ratio of 13.09 and a P/S ratio of 2.47, both significantly lower than the sector medians of 31.9 and 3.7 respectively, suggesting it is undervalued relative to its peers.
What is the outlook for Bristol-Myers Squibb's revenue growth?
Revenue growth for Bristol-Myers Squibb (BMY) is projected at 3.00% for the current year, but a decline of 3.00% is anticipated for next year. The company's next quarter revenue is estimated to grow by 1.00% year-over-year.
What do Wall Street analysts recommend for Bristol-Myers Squibb stock?
Wall Street analysts currently have a 'Hold' consensus for Bristol-Myers Squibb (BMY), with 17 out of 28 analysts rating it as 'Hold'. The median price target is $68.00, indicating a potential 15% upside from the current stock price.